Welcome to LookChem.com Sign In|Join Free

CAS

  • or
5-[(DIMETHYLAMINO)METHYL]-2-FURANMETHANOL is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals and acts as an inhibitor of monoamine oxidase B, a key enzyme involved in the breakdown of neurotransmitters in the brain.

15433-79-1

Post Buying Request

15433-79-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

15433-79-1 Usage

Uses

Used in Pharmaceutical Industry:
5-[(DIMETHYLAMINO)METHYL]-2-FURANMETHANOL is used as an intermediate in the synthesis of Ranitidine hydrochloride (R120000), a medication commonly used to treat conditions caused by excess stomach acid, such as ulcers and gastroesophageal reflux disease (GERD). Its role in the synthesis process is essential for the development of this widely prescribed drug.
Used in Neuropharmacology:
5-[(DIMETHYLAMINO)METHYL]-2-FURANMETHANOL is used as an inhibitor of monoamine oxidase B (MAO-B) for the treatment of neurological and psychiatric disorders. By inhibiting MAO-B, it helps regulate the levels of neurotransmitters like dopamine, norepinephrine, and serotonin, which are crucial for maintaining proper brain function and mood regulation. This application is particularly relevant in the treatment of conditions such as Parkinson's disease and major depressive disorder.

Check Digit Verification of cas no

The CAS Registry Mumber 15433-79-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,5,4,3 and 3 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 15433-79:
(7*1)+(6*5)+(5*4)+(4*3)+(3*3)+(2*7)+(1*9)=101
101 % 10 = 1
So 15433-79-1 is a valid CAS Registry Number.
InChI:InChI=1/C8H13NO2/c1-9(2)5-7-3-4-8(6-10)11-7/h3-4,10H,5-6H2,1-2H3

15433-79-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name [5-[(dimethylamino)methyl]furan-2-yl]methanol

1.2 Other means of identification

Product number -
Other names EINECS 239-445-2

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:15433-79-1 SDS

15433-79-1Relevant articles and documents

Synthesis of highly fluorescent and water soluble perylene bisimide

Boobalan, Gopal,Imran, Predhanekar Mohamed,Nagarajan, Samuthira

, p. 149 - 153 (2012)

Designed and synthesized a new highly water soluble N,N′-bis(2-((5- ((dimethylamino)methyl)furan-2-yl)methylthio)ethyl)perylene-3,4,9, 10-tetracarboxylic diimide from 2-((5-((dimethylamino)methyl)furan-2-yl) methylthio)ethanamine and perylene-3,4,9,10-tetracarboxylic dianhydride. The compound was characterized by 1H, 13C, 2D NMR, mass and IR techniques. The compound is highly fluorescent with good solubility in water and other polar solvents.

Targeting a dynamic protein-protein interaction: Fragment screening against the malaria myosin a motor complex

Douse, Christopher H.,Vrielink, Nina,Wenlin, Zhang,Cota, Ernesto,Tate, Edward W.

, p. 134 - 143 (2015)

Motility is a vital feature of the complex life cycle of Plasmodium falciparum, the apicomplexan parasite that causes human malaria. Processes such as host cell invasion are thought to be powered by a conserved actomyosin motor (containing myosin A or myoA), correct localization of which is dependent on a tight interaction with myosin A tail domain interacting protein (MTIP) at the inner membrane of the parasite. Although disruption of this protein-protein interaction represents an attractive means to investigate the putative roles of myoA-based motility and to inhibit the parasitic life cycle, no small molecules have been identified that bind to MTIP. Furthermore, it has not been possible to obtain a crystal structure of the free protein, which is highly dynamic and unstable in the absence of its natural myoA tail partner. Herein we report the de novo identification of the first molecules that bind to and stabilize MTIP via a fragment-based, integrated biophysical approach and structural investigations to examine the binding modes of hit compounds. The challenges of targeting such a dynamic system with traditional fragment screening workflows are addressed throughout.

Reductive Amination, Hydrogenation and Hydrodeoxygenation of 5-Hydroxymethylfurfural using Silica-supported Cobalt- Nanoparticles

Chandrashekhar, Vishwas G.,Natte, Kishore,Alenad, Asma M.,Alshammari, Ahmad S.,Kreyenschulte, Carsten,Jagadeesh, Rajenahally V.

, (2021/11/30)

Efficient and selective conversion of renewable feedstocks to essential chemicals and fuels applying green and sustainable catalytic processes is of central importance and attracts scientific interest. Among different biomass-based feedstocks, 5-hydroxymethylfurfural (HMF) represents valuable platform compound widely used for the synthesis of valuable chemicals, fuels, and polymers. Here we report cobalt nanoparticles catalyzed reductive amination, hydrogenation and hydrodeoxygenation of HMF to produce furan based primary, secondary and tertiary amines including N-methylamines as well as 2,5-bis(hydroxymethyl)furan, (5-methylfuran-2-yl)methanol and selected N-, O-, and S-containing heterocycles. Key to success for this HMF valorization is the use of reusable silica supported cobalt-based nanoparticles, which have been prepared by the immobilization and pyrolysis of Co-terephthalic acid-piperazine MOF template on silica.

Versatile CO-assisted direct reductive amination of 5-hydroxymethylfurfural catalyzed by a supported gold catalyst

Zhu, Ming-Ming,Tao, Lei,Zhang, Qi,Dong, Jing,Liu, Yong-Mei,He, He-Yong,Cao, Yong

, p. 3880 - 3887 (2017/08/22)

Reductive amination (RA) constitutes an attractive and practical strategy for discovering protocols capable of converting biomass into valuable N-containing compounds. Described herein is a versatile and sustainable RA of 5-hydroxymethyl-furfural (HMF), an important biomass-derived aldehyde, using abundant and cheaply available CO and water as reductants. A single phase rutile titania supported gold (Au/TiO2-R) catalyst is shown to efficiently catalyze this CO/H2O-mediated RA under mild and convenient conditions. With this system, a broad spectrum of primary and secondary amines can be used as suitable substrates and the desired reaction can proceed favourably in a highly chemoselective, efficient and atom-economical fashion. In particular, this protocol can also allow convenient access to bis(hydroxylmethylfurfuryl)-amines, a new group of furan-based monomers with great potential to form functional biopolymers with tunable properties. Moreover, this CO-assisted RA is more efficient (higher TON and TOF) and more eco-friendly (increased resource efficiency) than the previous state-of-the-art technique.

4 β-nitrogen substituted [...] amine podophyllotoxin derivative and its preparation method and application

-

Paragraph 0077-0078, (2016/11/28)

The invention provides a 4beta-nitrogen-substituted furan tertiary amine podophyllotoxin derivative. The structural general formula of the derivative is as shown in the specification. The compound is good in solubility and strong in anti-tumor activity and has an obvious suppression effect on the tumor cells such as lung cancer, malignant lymphoma, acute leukemia and the like. The invention also provides a preparation method of the compound.

Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease

Gao, Jie,Midde, Narasimha,Zhu, Jun,Terry, Alvin V.,McInnes, Campbell,Chapman, James M.

, p. 5573 - 5579 (2016/11/09)

Using molecular modeling and rationally designed structural modifications, the multi-target structure–activity relationship for a series of ranitidine analogs has been investigated. Incorporation of a variety of isosteric groups indicated that appropriate aromatic moieties provide optimal interactions with the hydrophobic and π–π interactions with the peripheral anionic site of the AChE active site. The SAR of a series of cyclic imides demonstrated that AChE inhibition is increased by additional aromatic rings, where 1,8-naphthalimide derivatives were the most potent analogs and other key determinants were revealed. In addition to improving AChE activity and chemical stability, structural modifications allowed determination of binding affinities and selectivities for M1–M4 receptors and butyrylcholinesterase (BuChE). These results as a whole indicate that the 4-nitropyridazine moiety of the JWS-USC-75IX parent ranitidine compound (JWS) can be replaced with other chemotypes while retaining effective AChE inhibition. These studies allowed investigation into multitargeted binding to key receptors and warrant further investigation into 1,8-naphthalimide ranitidine derivatives for the treatment of Alzheimer's disease.

Synthesis and evaluation of novel podophyllotoxin derivatives as potential antitumor agents

Cheng, Wei-Hua,Cao, Bo,Shang, Hai,Niu, Cong,Zhang, Li-Ming,Zhang, Zhong-Heng,Tian, Dan-Li,Zhang, Shi,Chen, Hong,Zou, Zhong-Mei

, p. 498 - 507 (2014/09/16)

Cancer multidrug resistance (MDR) is a common cause of treatment failure in cancer patients. Increased expression of permeability glycoprotein (P-gp), which is also known as MDR-1, is the main cause of multidrug resistance. Podophyllotoxin derivatives hold great promise in the battle to overcome multidrug resistance, as they can induce cytotoxicity through multiple mechanisms. Here, we synthesized sixteen novel podophyllotoxin derivatives and evaluated their cytotoxicities in human cancer cell lines, HeLa, K562 and K562/A02. Some of these compounds were more potent than etoposide, a clinically relevant inhibitor of DNA repair enzymes. In particular, compound 5p exhibited the most potent activity toward drug-resistant K562/A02 cells, as it robustly inhibited tumor cell proliferation and induced apoptosis. Furthermore, preliminary investigation suggested that 5p inhibited the expression of MDR-1 in K562/A02 cells more effectively than etoposide.

PREPARATION OF AMINOMETHYL FURANS AND ALKOXYMETHYL FURAN DERIVATIVES FROM CARBOHYDRATES

-

Page/Page column 11, (2012/06/30)

Described herein are single step methods of making various classes of alkylamine derivatives of furan and tetrahydrofuran by simultaneous contact of a sugar with H2, an acid catalyst and hydrogenation catalyst in the presence of an alkylamide solvent. The hydrogenation catalyst is a heterogeneous catalyst comprising a metal selected from the group consisting of Pt, Pd, and nickel. The acid catalysts may be homogeneous mineral acid or a heterogeneous acid catalyst on substrate. In a preferred practice the two catalysts are provided on a common heterogeneous bifunctional support. Using similar combinations of acid and hydrogenation catalysts, there is also described single step methods for making furandimethanol by simultaneously contacting a hexose with the two separate catalysts in the presence of H2 in an aprotic solvent, such as dimethylformamide. With the same catalyst system and similar reaction conditions, 2, 5 furan dialkylethers can also be made in a single step when the solvent includes an ROH alcohol.

PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF

-

Page/Page column 76, (2008/12/08)

The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.

QUINAZOLINE DERIVATIVES,PREPARATION METHODS AND USES THEREOF

-

Page/Page column 19-20, (2008/12/08)

The present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti- tumor medicament.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 15433-79-1